News, Links and Commentary
Saturday, October 29, 2005
Another Presentation on Avastin for Wet MD at AAO Meeting
The potential of the drug Avastin (bevacizumab) in treating patients with wet age-related macular degeneration is covered again in Doctor's Guide. Dr Robert Avery, an ophthalmologist at the California Retinal Consultants and Research Foundation, presented findings from a study of patients treated for wet MD with Avastin at the 2005 annual meeting of the American Academy of Ophthalmology.
"Our experience is limited by the small number of patients and the very short follow-up, but a rapid biologic effect is observed," Dr. Avery said. "It seems to penetrate the retina sufficiently for these effects."
He added that prospective clinical trials are needed to assess the safety and efficacy of bevacizumab. He noted that the long-term safety of this agent is not known.
'Intravitreal Bevacizumab (Avastin) Holds Promise for Retinal Vascular Diseases: Presented at AAO' (Doctor's Guide, 26 October 2005).
Comments:
Post a Comment
